Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,retainedEarnings,treasuryStock,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,accountsPayable,otherCurrentLiab,otherLiab,depreciation,changeToNetincome,changeToLiabilities,changeToOperatingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,currency,market,shortName,esgPopulated,tradeable,exchange,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,marketState,exchangeDataDelayedBy,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,longName,fullExchangeName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,epsTrailingTwelveMonths,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,GTHR,-7857284.0,25571300,,,-206241,,-206241,203275,0,-204595,-204595,,-1646,,,,0,0,204595,0,-1646,,-206241,-206241,23529776.0,7841507.0,-7857284.0,10262.0,25571.0,-31466202.0,53571.0,7841507.0,53571.0,9240.0,1022.0,81070.0,,,1320.0,55500.0,149421.0,,-7840485.0,en-US,US,EQUITY,False,Delayed Quote,USD,us_market,GENETHERA INC,False,False,PNK,0.0357,1630521491,-0.010299999,0.04085,0.046,0.0357,2953,PREPRE,0,4,-22.391302,0.0357 - 0.046,0.046,0.0,0.0,0,0,finmb_1738164,"GeneThera, Inc.",Other OTC,USD,114978,44457,0.0297,4.95,0.006 - 0.47,-0.4343,-0.9240426,0.006,0.47,-0.048,-0.307,0.040082857,-0.004382856,-0.10934491,0.039928984,-0.004228983,-0.10591261,912895,-0.11628664,15,America/New_York,EDT,-14400000,0.93,,,0.47,0.006,0.0401,0.0399,114.98k,44.46k,25.57M,,21.76M,14.50%,0.00%,,,,,,,,,,,0.00%,,"May 16, 2007",,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,"-4,052.84%",,,,,,-798.22k,-837.35k,-0.0480,,,,824.42k,,0.00,-0.31,,,Value,80035,Healthcare,2,"GeneThera, Inc., a biotechnology company, develops molecular assays and therapeutics for the detection and treatment of zoonotic diseases. It offers treatment for zoonotic diseases, such as COVID -19 disease; paratuberculosis (Johne's disease) that is in Stage III clinical phase; mad cow and chronic wasting diseases; and E.coli and salmonella infections, as well as develops vaccine for mycobacterium avian paratuberculosis infection. The company is based in Westminster, Colorado.",Westminster,720 587 5100,CO,1609372800,United States,http://www.genethera.net,86400,3051 West 105th Avenue,Biotechnology,Suite 350251
t-1,GTHR,-7706543.0,25571300,,,-161037,,-161037,136083,0,-132123,-132123,,-28914,,,,0,0,132123,0,-28914,,-161037,-161037,23475776.0,7692086.0,-7706543.0,11582.0,24071.0,-31259962.0,53572.0,7692087.0,53572.0,10560.0,1022.0,81070.0,1.0,-1.0,1320.0,1.0,148415.0,11301.0,-7691065.0,en-US,US,EQUITY,False,Delayed Quote,USD,us_market,GENETHERA INC,False,False,PNK,0.0357,1630521491,-0.010299999,0.04085,0.046,0.0357,2953,PREPRE,0,4,-22.391302,0.0357 - 0.046,0.046,0.0,0.0,0,0,finmb_1738164,"GeneThera, Inc.",Other OTC,USD,114978,44457,0.0297,4.95,0.006 - 0.47,-0.4343,-0.9240426,0.006,0.47,-0.048,-0.307,0.040082857,-0.004382856,-0.10934491,0.039928984,-0.004228983,-0.10591261,912895,-0.11628664,15,America/New_York,EDT,-14400000,0.93,,,0.47,0.006,0.0401,0.0399,114.98k,44.46k,25.57M,,21.76M,14.50%,0.00%,,,,,,,,,,,0.00%,,"May 16, 2007",,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,"-4,052.84%",,,,,,-798.22k,-837.35k,-0.0480,,,,824.42k,,0.00,-0.31,,,Value,80035,Healthcare,2,"GeneThera, Inc., a biotechnology company, develops molecular assays and therapeutics for the detection and treatment of zoonotic diseases. It offers treatment for zoonotic diseases, such as COVID -19 disease; paratuberculosis (Johne's disease) that is in Stage III clinical phase; mad cow and chronic wasting diseases; and E.coli and salmonella infections, as well as develops vaccine for mycobacterium avian paratuberculosis infection. The company is based in Westminster, Colorado.",Westminster,720 587 5100,CO,1609372800,United States,http://www.genethera.net,86400,3051 West 105th Avenue,Biotechnology,Suite 350251
t-2,GTHR,-7545509.0,25571300,,,-274366,,-274366,271400,0,-272720,-272720,,-1646,,,,0,0,272720,0,-1646,,-274366,-274366,23475772.0,7543673.0,-7545509.0,24203.0,24071.0,-31098925.0,53573.0,7543670.0,53573.0,11880.0,12323.0,81070.0,,3.0,1320.0,14956.0,266491.0,-8401.0,-7531347.0,en-US,US,EQUITY,False,Delayed Quote,USD,us_market,GENETHERA INC,False,False,PNK,0.0357,1630521491,-0.010299999,0.04085,0.046,0.0357,2953,PREPRE,0,4,-22.391302,0.0357 - 0.046,0.046,0.0,0.0,0,0,finmb_1738164,"GeneThera, Inc.",Other OTC,USD,114978,44457,0.0297,4.95,0.006 - 0.47,-0.4343,-0.9240426,0.006,0.47,-0.048,-0.307,0.040082857,-0.004382856,-0.10934491,0.039928984,-0.004228983,-0.10591261,912895,-0.11628664,15,America/New_York,EDT,-14400000,0.93,,,0.47,0.006,0.0401,0.0399,114.98k,44.46k,25.57M,,21.76M,14.50%,0.00%,,,,,,,,,,,0.00%,,"May 16, 2007",,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,"-4,052.84%",,,,,,-798.22k,-837.35k,-0.0480,,,,824.42k,,0.00,-0.31,,,Value,80035,Healthcare,2,"GeneThera, Inc., a biotechnology company, develops molecular assays and therapeutics for the detection and treatment of zoonotic diseases. It offers treatment for zoonotic diseases, such as COVID -19 disease; paratuberculosis (Johne's disease) that is in Stage III clinical phase; mad cow and chronic wasting diseases; and E.coli and salmonella infections, as well as develops vaccine for mycobacterium avian paratuberculosis infection. The company is based in Westminster, Colorado.",Westminster,720 587 5100,CO,1609372800,United States,http://www.genethera.net,86400,3051 West 105th Avenue,Biotechnology,Suite 350251
t-3,GTHR,-7286097.0,25571300,,,-195707,,-195707,192741,0,-194061,-194061,,-1646,,,,0,0,194061,0,-1646,,-195707,-195707,23448986.0,7274180.0,-7286097.0,14122.0,35904.0,-30824559.0,53572.0,7277180.0,53572.0,13200.0,922.0,28748.0,,-3000.0,1320.0,-1.0,198310.0,-3922.0,-7276258.0,en-US,US,EQUITY,False,Delayed Quote,USD,us_market,GENETHERA INC,False,False,PNK,0.0357,1630521491,-0.010299999,0.04085,0.046,0.0357,2953,PREPRE,0,4,-22.391302,0.0357 - 0.046,0.046,0.0,0.0,0,0,finmb_1738164,"GeneThera, Inc.",Other OTC,USD,114978,44457,0.0297,4.95,0.006 - 0.47,-0.4343,-0.9240426,0.006,0.47,-0.048,-0.307,0.040082857,-0.004382856,-0.10934491,0.039928984,-0.004228983,-0.10591261,912895,-0.11628664,15,America/New_York,EDT,-14400000,0.93,,,0.47,0.006,0.0401,0.0399,114.98k,44.46k,25.57M,,21.76M,14.50%,0.00%,,,,,,,,,,,0.00%,,"May 16, 2007",,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,"-4,052.84%",,,,,,-798.22k,-837.35k,-0.0480,,,,824.42k,,0.00,-0.31,,,Value,80035,Healthcare,2,"GeneThera, Inc., a biotechnology company, develops molecular assays and therapeutics for the detection and treatment of zoonotic diseases. It offers treatment for zoonotic diseases, such as COVID -19 disease; paratuberculosis (Johne's disease) that is in Stage III clinical phase; mad cow and chronic wasting diseases; and E.coli and salmonella infections, as well as develops vaccine for mycobacterium avian paratuberculosis infection. The company is based in Westminster, Colorado.",Westminster,720 587 5100,CO,1609372800,United States,http://www.genethera.net,86400,3051 West 105th Avenue,Biotechnology,Suite 350251
